4 research departments
750 employees
45 nationalities
55 research teams
16 ERC laureates
260 publications per year
24000 m² lab area

Support us through

Fondation universite de Strasbourg

Key figures

72 patents since 1995
11 licenses obtained since 2000
4 spin-off

Quick Links

Technology transfer


list of start-up since 2011 :


created in 2011, this company develops new treatments against muscular diseases (genetics such as DMD and chronic such as sarcopenia and cachexia). It has a unique stem cell differentiation technology that allows the massive and standardized production of different cell lines, including mature skeletal muscle cells.


renamed BRCell: created in 2011, RINGTECH's mission is to develop innovative cell-screening technologies to evaluate the effects of candidate-drug molecules for the pharmaceutical and research laboratories. RINGTECH technology aims to simplify, improve reliability and accelerate the testing of molecules with therapeutic potential. RINGTECH's technological innovation lies in the insertion of cells in "cellular eyepieces" allowing three-dimensional normalization and high-quality multi-parameter reading.


created in 2012, EPIGEX is a start-up that develops and markets innovative tools for the study of epigenetic diseases such as cancer, inflammation and autoimmune diseases. EPIGEX offers :

  • Innovative tools for research and screening of new therapeutic molecules
  • New technology for mapping of altered protein interactions in epigenetic diseases
  • new tumor markers capable of detecting the first signs of the disease at a time when the prognosis is positive.

Annapurna Therapeutics

AAVLIFE is renamed Annapurna Therapeutics and bought in 2016 by Avalanche biotech. Founded in 2014, AAV Life specializes in gene therapy for rare diseases, including Friedreich's ataxia, which combines progressive neurodegenerative disease, heart disease and an increased risk of diabetes.


created in 2015, RiboStruct develops a generic treatment for all genetic diseases when they are caused by a particular type of mutations, nonsense mutations (about 10-15 of cases) targeting the human ribosome through to the unique know-how in ribosome crystallography developed by Marat Yusupov and Gulnara Yusupova at the IGBMC. This new therapeutic approach, the transcription, is applicable whatever the gene concerned, unlike gene therapies that each target a particular gene.


Created in 2015, this project is led by Jocelyn Laporte, head of the "Physiopathology of neuromuscular diseases" team at the IGBMC. The Dynacure project concerns the development of a therapeutic strategy for Centronuclear Myopathies (CNM), a group of serious and very rare myopathies, for which no therapy exists today.

Imprimer Envoyer

Université de Strasbourg

IGBMC - CNRS UMR 7104 - Inserm U 1258
1 rue Laurent Fries / BP 10142 / 67404 Illkirch CEDEX / France Tél +33 (0)3 88 65 32 00 / Fax +33 (0)3 88 65 32 01 / directeur.igbmc@igbmc.fr